Table 3.

Least squares mean differences (T0–T24, %) in laboratory parameters and anthropometric measures between the two groups

		Control group (n. 123) Δ T0–T24 [%]	Treatment group (n. 122) Δ T0–T24 [%]	95% confidence interval	p
BMI	(kg/m2)	– 1.2 ± 0. 01	– 4.8 ± 0.4	2.201–6.466	< 0.01
HbA1c	(%)	– 3.5 ± 0. 4	– 8.2 ± 1.0	0.686–3.318	< 0.01
FPG	(%)	– 1.6 ± 0.9	– 7.7 ± 0.8	0.637–4.031	< 0.01
PPG	(%)	– 2.5 ± 1.8	– 8.6 ± 2.2	1.184–5.981	< 0.01
ASL	(%)	– 1.1 ± 1.0	– 30.6 ± 12.8	2.298–10.192	< 0.0001
ALT	(%)	– 1.4 ± 0.7	– 28.6 ± 2.0	1.873–9.483	< 0.0001
γ-GT	(%)	– 0.9 ± 0.2	– 20.2 ± 1.5	1.243–5.329	< 0.0001
ALP	(%)	– 0.3 ± 0.1	– 1.9 ± 1.5	0.335–2.661	< 0.049
Total cholesterol	(mg/dl)	– 2.5 ± 1.0	– 9.9 ± 1.1	0.682–5.919	< 0.001
HDL cholesterol	(mg/dl)	± 0.1 ± 0.4	± 1.9 ± 0.3	0.736–2.982	< 0.05
Triglyceride	(mg/dl)	– 2.5 ± 1.1	– 9.8 ± 0.6	0.912–3.112	< 0.01
LDL cholesterol	(mg/dl)	– 2.4 ± 0.6	– 9.9 ± 1.2	0.910–5.128	< 0.01
Platelet count	(n/μL)	– 0.9 ± 0.1	– 0.8 ± 0.1	0.349–0.916	n.s
Albumin	(g/dl)	± 0.2 ± 0.04	± 0.2 ± 0.04	0.337–0.621	n.s
eGFR	(ml/min/1.73m2)	– 0.4 ± 0.1	– 0.6 ± 0.1	0.399–0.917	n.s
HOMA-IR	–	– 5.2 ± 0.4	– 42.2 ± 0.6	0.789–4.235	< 0.0001
Insulin	(μIU/ml)	– 1.3 ± 0.5	– 38.6 ± 0.6	0.993–4.756	< 0.0001
C-peptide	(ng/ml)	– 0.4 ± 0.1	– 7.2 ± 0.4	0.346–1.878	< 0.05

ALP alkaline phosphatase, ALT alanine transferase, AST aspartate transferase, BMI body mass index, eGFR estimated glomerular filtration rate, FIB-4 Fibrosis (FIB)-4 Score, FLI Fatty Liver Index, FPG fasting plasma glucose, γ-GT gamma-glutamyl transferase, HbA1c hemoglobin A1C, HDL high-density lipoprotein, HOMA-IR homeostatic model assessment for insulin resistance, LDL low-density lipoprotein, NFS NAFLD (non-alcoholic fatty liver disease) Fibrosis Score, PPG postprandial glycemia